Regen Biopharma Inc (RGBPP) financial statements (2021 and earlier)

Company profile

Business Address 4700 SPRING ST #304
LA MESA, CA 91942
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8270 39 
Cash and cash equivalents8270 39 
Receivables8107 10
Prepaid expense834 10 
Other undisclosed current assets1967 1210
Total current assets:43478 6211
Noncurrent Assets
Other undisclosed noncurrent assets166466 158 
Total noncurrent assets:166466 158 
TOTAL ASSETS:209944 22011
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:656591107212
Accounts payable81496 263
Accrued liabilities  1010 
Employee-related liabilities41 368
Other undisclosed accounts payable and accrued liabilities57194   
Debt0 50 6
Due to related parties01111432090
Other undisclosed current liabilities8,0175,161 22632
Total current liabilities:8,6745,863203318140
Noncurrent Liabilities
Long-term debt and lease obligation656332   
Long-term debt, excluding current maturities656332   
Other undisclosed noncurrent liabilities1    
Total noncurrent liabilities:657332   
Total liabilities:9,3316,196203318140
Stockholders' equity
Stockholders' equity attributable to parent, including:(9,122)(5,251) (97)(130)
Preferred stock   6 
Common stock1814 115
Additional paid in capital7,5186,643 11,664485
Accumulated other comprehensive income (loss)5388 (34) 
Accumulated deficit(17,457)(12,742) (12,474)(1,279)
Other additional capital729729 729659
Other undisclosed stockholders' equity attributable to parent1817 0 
Other undisclosed stockholders' equity 0   
Total stockholders' equity:(9,122)(5,251) (97)(130)
TOTAL LIABILITIES AND EQUITY:20994420322011

Income statement (P&L) ($ in thousands)

9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Revenues100110 192 
Other income 51  
Cost of revenue(408)(649) (575)(159)
Gross profit:(308)(539) (383)(159)
Operating expenses(1,118)(1,972) (1,597)(548)
Other operating expense, net
(Other Expenses)
    (14)
Other undisclosed operating income    14
Operating loss:(1,426)(2,511) (1,979)(706)
Nonoperating income
(Debt Instrument, Convertible, Beneficial Conversion Feature)
  50  
Interest and debt expense(363)(99) (22)(2)
Net income (loss):(1,789)(2,610)50(2,001)(709)
Other undisclosed net loss attributable to parent(2,926)(3,229)  (48)
Net income (loss) available to common stockholders, diluted:(4,715)(5,839)50(2,001)(756)

Comprehensive Income ($ in thousands)

9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Net income (loss):(1,789)(2,610)50(2,001)(709)
Other comprehensive income (loss)(35)168 (34) 
Comprehensive income (loss):(1,824)(2,442)50(2,035)(709)
Other undisclosed comprehensive loss, net of tax, attributable to parent(2,926)(3,229) (9,194) 
Comprehensive income (loss), net of tax, attributable to parent:(4,750)(5,671)50(11,229)(709)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: